Santen Pharmaceutical Co (TSE:4536) Cyclically Adjusted Revenue per Share: 円738.15 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4536 Santen Pharmaceutical Co Ltd TSE:4536
83 GF Score
Price 円1,960.00
GF Value 円1,686.28
Valuation Modestly Overvalued
! 1 Warning Sign
View Full Analysis

What is Santen Pharmaceutical Co Cyclically Adjusted Revenue per Share?

Santen Pharmaceutical Co TSE:4536 -0.61% 83 Cyclically Adjusted Revenue per Share is 円738.15 as of Mar. 2026. GuruFocus rates TSE:4536 with a GF Score™ of 83/100 and a GF Value™ of 円1,686.28 (Modestly Overvalued). The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Santen Pharmaceutical Co's adjusted revenue per share for the three months ended in Mar. 2026 was 円246.247. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is 円738.15 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Santen Pharmaceutical Co's average Cyclically Adjusted Revenue Growth Rate was 6.30% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 9.00% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 9.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Santen Pharmaceutical Co was 10.70% per year. The lowest was 8.40% per year. And the median was 9.30% per year.

As of today (2026-07-28), Santen Pharmaceutical Co's current stock price is 円1960.00. Santen Pharmaceutical Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was 円738.15. Santen Pharmaceutical Co's Cyclically Adjusted PS Ratio of today is 2.66.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Santen Pharmaceutical Co was 5.62. The lowest was 1.77. And the median was 2.89.


Santen Pharmaceutical Co  (TSE:4536) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Santen Pharmaceutical Co's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=1960.00/738.15
=2.66

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Santen Pharmaceutical Co was 5.62. The lowest was 1.77. And the median was 2.89.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Santen Pharmaceutical Co Cyclically Adjusted Revenue per Share Related Terms


Santen Pharmaceutical Co Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Santen Pharmaceutical Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Santen Pharmaceutical Co Cyclically Adjusted Revenue per Share Chart

Santen Pharmaceutical Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 511.91 570.54 629.83 694.23 738.15

Santen Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 694.23 705.07 714.00 728.22 738.15

TSE:4536 vs LLY, JNJ, ABBV: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - General subindustry, Santen Pharmaceutical Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Santen Pharmaceutical Co Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Santen Pharmaceutical Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Santen Pharmaceutical Co's Cyclically Adjusted PS Ratio falls into.


TSE:4536
83GF Score
Santen Pharmaceutical Co Ltd TSE:4536
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Santen Pharmaceutical Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Santen Pharmaceutical Co's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=246.247/112.7000*112.7000
=246.247

Current CPI (Mar. 2026) = 112.7000.

Santen Pharmaceutical Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 120.275 98.100 138.175
201609 115.158 98.000 132.432
201612 129.256 98.400 148.040
201703 118.781 98.100 136.459
201706 137.248 98.500 157.034
201709 134.447 98.800 153.362
201712 141.718 99.400 160.680
201803 138.090 99.200 156.882
201806 138.396 99.200 157.230
201809 141.744 99.900 159.905
201812 144.167 99.700 162.965
201903 150.190 99.700 169.773
201906 147.762 99.800 166.861
201909 148.984 100.100 167.737
201912 158.728 100.500 177.996
202003 148.029 100.300 166.330
202006 143.780 99.900 162.202
202009 153.196 99.900 172.825
202012 157.034 99.300 178.225
202103 169.391 99.900 191.095
202106 162.332 99.500 183.868
202109 159.241 100.100 179.285
202112 167.381 100.100 188.450
202203 175.918 101.100 196.102
202206 164.943 101.800 182.604
202209 166.851 103.100 182.387
202212 183.341 104.100 198.487
202303 209.903 104.400 226.591
202306 193.565 105.200 207.365
202309 203.044 106.200 215.471
202312 217.026 106.800 229.015
202403 217.081 107.200 228.219
202406 207.443 108.200 216.070
202409 201.253 108.900 208.276
202412 216.830 110.700 220.747
202503 220.853 111.100 224.034
202506 202.071 111.700 203.880
202509 206.831 112.000 208.124
202512 220.663 113.000 220.077
202603 246.247 112.700 246.247

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of 円738.15 mean?
Santen Pharmaceutical Co (TSE:4536) has a Cyclically Adjusted Revenue per Share of 円738.15 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Santen Pharmaceutical Co and its competitors.
Is Santen Pharmaceutical Co's Cyclically Adjusted Revenue per Share too high?
Santen Pharmaceutical Co's current Cyclically Adjusted Revenue per Share is 円738.15. Overall, Santen Pharmaceutical Co has a GF Score™ of 83/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Santen Pharmaceutical Co's Cyclically Adjusted Revenue per Share compare to LLY and JNJ?
Santen Pharmaceutical Co's Cyclically Adjusted Revenue per Share of 円738.15 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Santen Pharmaceutical Co and its competitors. Santen Pharmaceutical Co's current Cyclically Adjusted Revenue per Share is 円738.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Santen Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Santen Pharmaceutical Co (TSE:4536) is currently considered Modestly Overvalued. The stock's GF Value™ is 円1,686.28, compared to a current price of 円1,960.00 — trading 16.2% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is 円738.15. Santen Pharmaceutical Co's overall GF Score™ is 83/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Santen Pharmaceutical Co (TSE:4536), the current Cyclically Adjusted Revenue per Share is 円738.15 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Santen Pharmaceutical Co (TSE:4536) Overvalued in 2026?

Based on GuruFocus' analysis, Santen Pharmaceutical Co stock appears to be overvalued. The current stock price of 円1,960.00 is trading 16.2% above its estimated GF Value™ of 円1,686.28. GuruFocus considers Santen Pharmaceutical Co to be Modestly Overvalued.

Key valuation signals for TSE:4536:

  • Cyclically Adjusted Revenue per Share: 円738.15
  • GF Value™: 円1,686.28 vs. price of 円1,960.00 (16.2% above fair value)
  • GF Score™: 83/100 with 1 warning sign

No single metric tells the full story. See the TSE:4536 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Santen Pharmaceutical Co Business Description

Other Exchanges SNPHY:USA
Address 4-20 Ofukacho, Grand Front Osaka Tower A, Kita-ku, Osaka Prefecture, Osaka, JPN, 530-8552
Santen Pharmaceutical Co Ltd is a drug manufacturing company that focuses on ophthalmic products. The company provides a wide range of prescription and over-the-counter eye care products, including treatments for glaucoma, dry eye, and allergies. It also develops surgical and diagnostic devices related to eye care.
83GF Score

Get the complete analysis for TSE:4536

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円1,960.00
Price
円1,686.28
GF Value